Navigation Links
New Research Reveals Mechanism By Which TNFerade(TM) Suppresses Metastases
Date:3/3/2010

GAITHERSBURG, Md., March 3 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced the publication of new preclinical research revealing mechanisms by which TNFerade(TM) suppresses cancer metastases through activation of the immune system.

This preclinical study, "Ad.Egr-TNF and Local Ionizing Radiation Suppress Metastases by Interferon-Beta-Dependent Activation of Antigen-specific CD8+ T Cells," authored by investigators from the University of Chicago and Harvard Medical School, appears in the recent issue of Molecular Therapy. The results illustrate that local treatment of an animal tumor with TNFerade suppresses metastases to lymph nodes by activating CD8+ T cells. Activation of these anti-tumor cells is mediated by Interferon-Beta, a known potent immune regulator.

"Although enhanced local control of cancer can contribute to improvements in patient survival, any suppression of metastases is an important aspect of cancer treatment. These exciting preclinical data may help explain the encouraging results being seen with TNFerade in the clinic," noted Mark Thornton, M.D., M.P.H., Ph.D., GenVec's Senior Vice President of Product Development.

About TNFerade(TM)

TNFerade is an adenovector, or DNA carrier, which contains the gene for tumor necrosis factor-alpha (TNF-alpha), an immune system protein with potent and well-documented anti-cancer effects, for direct injection into tumors. After administration, TNFerade stimulates the production of TNF-alpha in the tumor. GenVec is developing TNFerade for use in combination with radiation and/or chemotherapy for the treatment of various cancers.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. In addition, GenVec uses its proprietary adenovector technology to develop vaccines for infectious diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. GenVec also discovers and develops novel treatments for hearing loss and balance disorders through a worldwide collaboration with Novartis. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

    Investor Contact:
    GenVec, Inc.
    Danielle M. DiPirro
    (301) 944-1877
    ddipirro@genvec.com

    Media Contact:
    Tiberend Strategic Advisors, Inc.
    Andrew Mielach
    (212) 827-0020
    amielach@tiberendstrategicadvisors.com

SOURCE GenVec, Inc.

Back to top

RELATED LINKS
http://www.genvec.com

'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sorting device for analyzing biological reactions puts the power of a lab in a researchers pocket
2. U.S. Government Awards DuPont, Partners with Technology Investment Agreement for Macroalgae-to-Biobutanol Research
3. New Source for Science Funding: BenchFly Pioneers Search for Research Program
4. Stem Cell Innovations to Provide Research and Assay Services to Agennix.
5. Sunlight Research(TM), Releases its Osiris Therapeutics Stem Cell Patent Report
6. No New Findings in Atrazine Study Promoted by Discredited Researcher, According to the Hudson Institute Center for Global Food Issues
7. Funds Boost Research into Causes, Interventions for Age-Related Cognitive Decline
8. Stephen Coles is Recognized by Continental Whos Who Among Health Care Research Professionals
9. febits miRBase 14 Geniom-Biochip Now With 58 Additional New Sequences Available for Cancer Research
10. Researchers gain detailed insight into failing heart cells using new nano technique
11. Texas-Based Consortium Announces Project GreenVax: A Groundbreaking Vaccine Manufacturing Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb. 22, 2017  PrimeVax Immuno-Oncology, Inc. announced ... presenting at the Annual Biocom Global Life Science Partnering ... at 11:15 AM, at the Torrey Pines Lodge, in ... the organizers at Biocom who have chosen our company, ... of biotechnology companies, investors, and clinical researchers," said Mr. ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... provider of women’s health, primary care, and specialty education, announced today it ... Education (ACCME). ACCME’s Accreditation with Commendation is a six-year accreditation and is ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... and scientists from around the world, is pleased to announce the 2nd annual ... 23, 2017. This premier, online-only conference focused on the development and advancements in ...
(Date:2/22/2017)... 22, 2017 Dublin ... "Global Biological Crop Protection (Bio-Pesticide) Market-By Type, By Application, By End ... to their offering. ... Global Biological Crop Protection Market is forecasted to grow at ... growth in biopesticide or biological crop protection market is driven by ...
Breaking Biology Technology:
(Date:2/7/2017)... Ind. , Feb. 7, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the LEERINK ... New York Palace Hotel on Wednesday, February 15, 2017 ... live webcast of the presentation can be accessed at ... replay following the conference via Zimmer Biomet,s Investor Relations ...
(Date:2/6/2017)... According to Acuity Market Intelligence, ongoing ... to continue to embrace biometric and digital identification ... Border Control (ABC) eGates and 1436 Automated Passport ... 163 ports of entry across the globe. Deployments ... combined CAGR of 37%. APC Kiosks reached 75% ...
(Date:2/3/2017)... A new independent identity strategy consultancy firm ... . Designed to fill a critical niche in technical ... partners Mark Crego and Janice Kephart ... identity expertise that span federal governments, the 9/11 Commission, ... combined expertise has a common theme born from a ...
Breaking Biology News(10 mins):